92.83 USD
+0.6 (+0.65%)
92.83 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IRMD. IRMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. IRMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IRMD is not valued too expensively and it also shows a decent growth rate. With these ratings, IRMD could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
IRMD had a positive operating cash flow in the past year.
Each year in the past 5 years IRMD has been profitable.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 18.47%, IRMD belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
IRMD has a Return On Equity of 21.54%. This is amongst the best in the industry. IRMD outperforms 94.15% of its industry peers.
IRMD has a Return On Invested Capital of 19.30%. This is amongst the best in the industry. IRMD outperforms 97.34% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 8.71%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.31%, IRMD belongs to the top of the industry, outperforming 95.21% of the companies in the same industry.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
IRMD's Operating Margin of 30.87% is amongst the best of the industry. IRMD outperforms 97.87% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
IRMD has a better Gross Margin (77.07%) than 89.36% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
IRMD has more shares outstanding than it did 1 year ago.
IRMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRMD has an Altman-Z score of 46.26. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 46.26, IRMD belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 46.26 |
ROIC/WACC2.23
WACC8.64%
2.3 Liquidity
IRMD has a Current Ratio of 6.64. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IRMD (6.64) is better than 84.04% of its industry peers.
IRMD has a Quick Ratio of 5.72. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD's Quick ratio of 5.72 is amongst the best of the industry. IRMD outperforms 85.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.75%, which is quite good.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 12.91% in the last year.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
The Earnings Per Share is expected to grow by 9.26% on average over the next years. This is quite good.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.97% yearly.
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 51.01 indicates a quite expensive valuation of IRMD.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 69.68% of the companies are valued more expensively.
IRMD is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 43.44, IRMD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 70.21% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.12. IRMD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.01 | ||
| Fwd PE | 43.44 |
4.2 Price Multiples
IRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 68.09% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than 70.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 84.64 | ||
| EV/EBITDA | 43.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)4.08
PEG (5Y)3.66
EPS Next 2Y13.8%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
With a yearly dividend of 0.78%, IRMD is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.73, IRMD pays a better dividend. On top of this IRMD pays more dividend than 92.02% of the companies listed in the same industry.
With a Dividend Yield of 0.78, IRMD pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
92.83
+0.6 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-1.59%
Ins Owners36.81%
Ins Owner Change-1.83%
Market Cap1.18B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target100.98 (8.78%)
Short Float %2.49%
Short Ratio3.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)34.69%
PT rev (3m)34.69%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)-2.04%
EPS NY rev (1m)-1.09%
EPS NY rev (3m)-1.62%
Revenue NQ rev (1m)5.37%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.01 | ||
| Fwd PE | 43.44 | ||
| P/S | 14.67 | ||
| P/FCF | 84.64 | ||
| P/OCF | 47.21 | ||
| P/B | 12.01 | ||
| P/tB | 12.43 | ||
| EV/EBITDA | 43.52 |
EPS(TTM)1.82
EY1.96%
EPS(NY)2.14
Fwd EY2.3%
FCF(TTM)1.1
FCFY1.18%
OCF(TTM)1.97
OCFY2.12%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)4.08
PEG (5Y)3.66
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 46.26 |
F-Score4
WACC8.64%
ROIC/WACC2.23
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.59%.